Home Page
Cipla partners with Qilu to license, supply Keytruda biosimilar in US
Cipla's US subsidiary Invagen Pharmaceuticals will market Qilu Pharmaceutical's QL2107, a biosimilar to Merck's cancer drug Keytruda, in the United States
Shown as published in the source's RSS feed. IndiaAIFounders doesn't link out to third-party sites — this is the complete detail available from the feed itself.